Welcome to our dedicated page for Predictive Oncology SEC filings (Ticker: POAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Axe Compute Inc., formerly Predictive Oncology Inc., filings document the issuer's completed strategic transformation into a GPU compute infrastructure and digital asset treasury company. Form 8-K disclosures cover operating and financial results, capital raised for the digital asset treasury strategy, and material-event reporting tied to enterprise AI compute infrastructure.
The filings also document governance changes, executive appointments and employment arrangements, shareholder voting matters, capital-structure disclosures, and contract announcements involving dedicated NVIDIA GPU clusters and AI-focused storage for large-scale model training, fine-tuning, and inference workloads.
Predictive Oncology Inc. (POAI) set its Annual Meeting for November 25, 2025 to vote on key items including board elections, auditor ratification, equity plan changes, and a large share issuance tied to pre-funded warrants. Stockholders of record as of October 24, 2025 (3,501,430 shares outstanding) may vote.
The ballot seeks: (1) election of two Class I directors; (2) ratification of KPMG as independent auditor for fiscal 2025; (3) an amendment to the 2024 Equity Incentive Plan to lift the reserve from 66,667 to 1,066,667 shares and cap incentive stock options at 500,000; (4) approval, under Nasdaq Listing Rule 5635(a), of the issuance of 14,903,393 shares of common stock upon exercise of pre-funded warrants to purchase an equal number of shares; and (5) a non-binding say‑on‑pay vote.
The company notes an overhang of 1.5% as of October 13, 2025, which would rise to approximately 24% if the plan amendment to 1,066,667 shares is approved, before any additional shares from pre-funded warrant exercises. A quorum requires 1,167,144 shares present or represented by proxy.
Predictive Oncology Inc. filed a resale registration covering up to 5,970,181 shares of common stock, to be sold from time to time by the selling stockholders after effectiveness. The company is not offering any shares.
The registered amount includes 3,365,690 PIPE Shares issued in August and September private placements, plus 2,604,491 shares issuable upon warrant exercise, consisting of 1,037,250 Cash PIPE Warrant Shares, 218,335 Agent Warrant Shares, and 1,348,906 Advisor Warrant Shares.
No proceeds will go to the company from stockholder resales. The company would receive cash only upon warrant exercises. The Cash PIPE Warrants carry a nominal $0.01 per-share exercise price; Agent and Advisor Warrants are exercisable at $11.6265 per share. POAI trades on Nasdaq; the last reported price was $9.30 per share on October 21, 2025.
Predictive Oncology Inc. filed a resale registration covering up to 14,903,393 shares of common stock underlying pre-funded warrants issued under a September 29, 2025 securities purchase agreement. The shares may be sold from time to time by the selling stockholders named in the prospectus.
The company is not offering any shares and will not receive proceeds from sales by the selling stockholders; it would receive only any cash paid upon warrant exercise. The warrants carry a $0.01 per share exercise price, have no expiration, and include a 19.99% beneficial ownership limitation. Exercise of these warrants is subject to shareholder approval for the underlying share issuance.
As context, the company’s Nasdaq ticker is POAI, and the last reported sale price was $9.30 per share on October 21, 2025. The filing notes a recent 1-for-15 reverse stock split effective September 30, 2025, and outlines a separate cash PIPE and a crypto-funded PIPE that introduced these pre-funded warrants. The plan of distribution permits various sale methods by the selling holders.
Predictive Oncology Inc. (POAI) filed a Form 3 for a director, the initial statement of beneficial ownership under Section 16. The filing states no securities are beneficially owned as of the event date 10/07/2025. The submission includes an Exhibit 24.1 Power of Attorney, and was signed by Josh Blacher, Attorney-in-Fact. This is an administrative disclosure and does not reflect a transaction.
Predictive Oncology (POAI) filed a Form 3 initial statement of beneficial ownership. The reporting person serves as Chief Investment Officer and indicated no securities are beneficially owned as of the event date 10/08/2025.
The filing includes Exhibit 24.1, a Power of Attorney, and was submitted as a single‑person filing.
Predictive Oncology set its 2025 annual meeting for November 25, 2025, in Pittsburgh at DLA Piper LLP (US). Stockholders of record on October 24, 2025 will be entitled to vote.
Stockholder proposals and proxy access requests must be received by October 26, 2025. The company expects to mail definitive proxy materials on or about November 3, 2025 and may supplement those materials, and if necessary postpone the meeting, to address any timely proposals.
Predictive Oncology Inc. filed an 8-K describing a press release issued on October 8, 2025. The release announced the closing of two private placements on October 7, 2025 and the company’s adoption of a digital asset treasury strategy, signaling a change in how it may hold part of its treasury assets. The press release is furnished under Regulation FD and attached as Exhibit 99.1, with most of its content (excluding the fifth and sixth paragraphs) also treated as an “Other Event” disclosure.
Predictive Oncology Inc. disclosed material transactions tied to private placements that include cash and cryptocurrency investments subject to customary closing conditions. The company agreed to issue placement agent warrants to purchase approximately 3.3 million shares exercisable at $0.7751 for five years and to pay a 5% cash fee to the placement agent for gross cash proceeds (excluding digital-asset proceeds). Strategic advisor warrants equal to approximately 20.3 million shares (about 7% of the securities sold) will be issued, exercisable at $0.7751 for five years and carrying a beneficial ownership cap of 4.99% (or optionally 9.99%). A Side Letter with DCI Foundation requires DCI to cure issues with locked crypto within five business days and to deliver an additional 20% of ATH tokens bought on the open market within 30 days of each purchase. The company amended bylaws effective September 26, 2025 to cap the board at seven directors. Various form agreements and exhibits were filed.
Predictive Oncology Inc. reported that it has issued a press release announcing two private placements and the adoption of a digital asset treasury strategy. The company states that it plans to maintain its existing lines of business while also pursuing this new approach to managing part of its treasury in digital assets. These updates are provided for information purposes under Regulation FD and, as described, are not being treated as filed financial information under securities law.